Page 6,801«..1020..6,8006,8016,8026,803..6,8106,820..»

MS liberation treatment offers ‘no measurable change’, study finds

Posted: Published on June 8th, 2012

TORONTO Patients who underwent the so-called liberation treatment for multiple sclerosis experienced no measurable benefit from the procedure, a study commissioned by the government of Newfoundland and Labrador found. The results of the small, observational study were announced Wednesday in St. Johns by lead investigator Dr. William Pryse-Phillips, a professor emeritus of neurology at Newfoundlands Memorial University. Pryse-Phillips said he had gone into the study hopeful the treatment might have something to offer his MS patients, but completed it convinced the people who had the vein-opening procedure didnt experience any gains. I am disappointed. I had hoped. I cannot recommend this therapy on the basis of these results at this time, he said during a news conference, the video of which is posted on the Department of Health and Community Services website. The province spent $400,000 on the study, which compared 30 patients with MS who had travelled outside the province to have the therapy and 10 who did not. Participants were subjected to an array of tests before the treatment and then at intervals of one month, three months, six months and one year post-procedure. It was an attempt to test a theory that has driven a wedge between … Continue reading

Posted in MS Treatment | Comments Off on MS liberation treatment offers ‘no measurable change’, study finds

Researchers assemble genetic map of an unborn child

Posted: Published on June 8th, 2012

SEATTLE -- Researchers at the University of Washington have assembled the first comprehensive genetic map of an unborn child -- a development that could help usher in a new era of prenatal testing. By analyzing fetal DNA circulating in the mother's blood, the scientists were able to sequence the baby's genome 18 weeks into the pregnancy. The technique also worked at eight weeks, with slightly lower sensitivity. Because the approach requires only a blood sample from the mother and saliva from the father, it poses none of the miscarriage risk associated with invasive tests such as amniocentesis. And while most existing prenatal tests are designed to check for single disorders, including Down syndrome, a full-gene scan has the power to reveal a wide range of potential problems before birth, said lead author Jacob Kitzman, a doctoral student in genetics. "It's much more comprehensive." The procedure is still several years away from commercialization, project leader Jay Shendure said. But the UW study, published in the June 6 issue of Science Translational Medicine, marks a significant step forward in technology that's been developing over the past several years -- and which worries some people, said Marcy Darnovsky of the Center for Genetics … Continue reading

Comments Off on Researchers assemble genetic map of an unborn child

New role for p53 genetic mutation — initiation of prostate cancer

Posted: Published on June 8th, 2012

ScienceDaily (June 7, 2012) A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease. The study was published online in the journal Disease Models & Mechanisms and will appear in the November 2012 print edition in an article titled, "Initiation of prostate cancer in mice by Tp53R270H: Evidence for an alternate molecular progression." "Our team found a molecular pathway to prostate cancer that differs from the current conventional wisdom of how the disease develops," said Alexander Borowsky, associate professor of pathology and laboratory medicine and principal investigator of the study. "With this new understanding, research can go in new directions to possibly develop new diagnostics and refine therapy." Prostate cancer is the leading cancer diagnosis in men in the United States. Although it is curable in about 80 percent of men with localized disease, the rate is much lower if the cancer is highly virulent and … Continue reading

Comments Off on New role for p53 genetic mutation — initiation of prostate cancer

Scientists map baby’s genetic code in womb

Posted: Published on June 8th, 2012

Scientists map babys genetic code in womb By John von Radowitz Friday, June 08, 2012 An unborn babys whole genetic code has been mapped in the womb using DNA taken from its parents. The technique could in future make it possible to swiftly scan for some 3,500 genetic disorders before birth, without physically disturbing either foetus or mother. But scientists acknowledge the ability to sequence a babys whole genome in the womb has as yet unresolved ethical implications. It could produce a wealth of data relating to a babys future health. At the same time, difficult questions may be raised about the moral case for termination. Most pre-natal genetic screening currently involves tapping fluid from the foetal sac, or taking placental samples. Such invasive methods can only identify a small number of birth defects including Downs syndrome, and spina bifida. They also pose risks for both mother and child. But there are thousands of rarer genetic conditions that are seldom spotted until they start producing symptoms. The new research involved analysing DNA shed by the foetus and floating in the mothers bloodstream. Blood sample DNA from the mother was also studied as well as DNA extracted from the fathers saliva. … Continue reading

Comments Off on Scientists map baby’s genetic code in womb

Preclinical Research with Proteonomix’s UMK-121 Featured in Oral Presentation at the International Society for …

Posted: Published on June 8th, 2012

HAWTHORNE, N.J.--(BUSINESS WIRE)-- Proteonomix, Inc. (PROTE), a biotechnology company focused on developing therapeutics based upon human cells and their derivatives, announces the oral presentation by Chief Scientific Officer Ian McNiece, Ph.D., of research related to the Companys UMK-121 technology today at the International Society for Cellular Therapy (ISCT) 18th Annual Meeting underway in Seattle. The 2012 ISCT Annual Meeting in Seattle celebrates the Societys 20th anniversary and has attracted a record number of delegates representing more than 40 countries, stated ISCT Executive Director Queenie Jang. The ISCT Annual Meeting is the largest translational cell therapy-focused meeting in the world and is intended to showcase the most current technology regarding a wide range of cellular therapies. Attendees included clinicians, scientists, regulatory professionals and industry personnel. The ISCT received hundreds of abstracts of which only 36 were accepted for oral presentation at the Annual Meeting. We are delighted that our abstract Mobilization of Mesenchymal Stem Cells from the Bone Marrow to Peripheral Blood was among those chosen for oral presentation at this prestigious conference, said Dr. McNiece. Mesenchymal stem cells, which are produced in bone marrow, are showing promise in the treatment of many diseases. This research demonstrated the ability of combinations … Continue reading

Posted in Mesenchymal Stem Cells | Comments Off on Preclinical Research with Proteonomix’s UMK-121 Featured in Oral Presentation at the International Society for …

Making Headway in the Eye Transplant Field

Posted: Published on June 8th, 2012

Eye transplants have long been viewed as a potential way to restore sight in some patients with certain eye conditions. Recently, two patients have received transplants of eye stem cells in a clinical trial. These patients did not wake up from surgery to instantly see a health practitioner wearing nursing scrubs in front of them, however. It will take some months to find out whether this surgery can be considered successful or not. A lot of people in the healthcare field are keeping their fingers crossed for these two patients. This technique was developed by specialists in Scotland to help reverse blindness caused by damage to the cornea. It was funded by the Chief Scientist Office and the UK Stem Cell Foundation and Scottish Enterprise. Up until this clinical trial, there was only one treatment available and that was to transplant cornea tissue donated by an organ donor. A woman from Edinburgh is one of the patients that has received this transplant. She suffers from corneal blindness and if this transplant proves to be successful it will transform her life. It won't only be her life that will be transformed, however, since many other patients suffering from corneal blindness are … Continue reading

Posted in Femtomedicine | Comments Off on Making Headway in the Eye Transplant Field

Experts Agree That a Disease-Modifying Therapy is the Greatest Unmet Need in the Treatment of Duchenne Muscular …

Posted: Published on June 7th, 2012

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the worlds leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that interviewed experts unanimously identify a disease-modifying therapy as the highest unmet need in the treatment of Duchenne muscular dystrophy (DMD). Duchenne is the most common form of muscular dystrophy in children. Glucocorticoid treatment is the only available therapy for the treatment of DMD, said Decision Resources Analyst Richa Mukherjee, M.Sc., M.Phil., Ph.D. Its a symptomatic therapy that does not target the cause of the disease and its use is often accompanied by concerning side effects. The lack of a disease-modifying therapy to treat DMD presents a high unmet need for drug developers. According to Niche Markets and Rare Diseases: Muscular Dystrophy, Decision Resources forecasts the launch of four new agents to treat DMD by 2021. These therapies include GlaxoSmithKline/Prosensas GSK-2402968/PRO-051/drisapersen, Santhera/Takeda's Catena/Sovirmas idebenone, AVI BioPharmas eteplirsen/AVI-4658 and Prosensas PRO-044. Of these therapies, GSK-2402968, eteplirsen and PRO-044 are disease-modifying therapies that will heavily saturate their target patient segments however, given the small size of these segments, the market will still be very receptive to novel disease-modifying agents. The DMD market will grow as a result of polytherapy as patients … Continue reading

Posted in Muscular Dystrophy Treatment | Comments Off on Experts Agree That a Disease-Modifying Therapy is the Greatest Unmet Need in the Treatment of Duchenne Muscular …

Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy

Posted: Published on June 7th, 2012

LOUVAIN LA NEUVE, Belgium, June 7, 2012 /PRNewswire/ -- Treatment of Refractory Epilepsy by Vagus Nerve Stimulation to be available in Europe Neurotech s.a. (http://www.neurotech-int.eu), a Belgium based developer and manufacturer of neurostimulation devices, announces that it has obtained the European CE Mark for its ADNS-300 system dedicated to the treatment of refractory epilepsy. The surgically implanted ADNS-300 system delivers mild electrical pulses to the vagus nerve in the neck. Operating as a pacemaker, it produces stimulation towards the brain. "Advens therapy" uses the ADNS-300 stimulator as a therapeutic option for those patients who are refractory to anti-epileptic drugs and are not eligible for epilepsy (brain) surgery. The ADNS-300 is the world's first rechargeable neurostimulator for vagus nerve stimulation. The device includes an innovative electrode and a promising "sensing" feature that may prove to be a significant technological breakthrough in the control of response to the therapy. Patients use a remote controller and charger to turn the system on/off and to recharge the neurostimulator. "Rechargeable systems may prove to be more cost-effective, especially if surgical operations to replace batteries are avoided over time. This helps patients to maintain a more independent life, with a lower risk of potential complications associated … Continue reading

Comments Off on Neurotech s.a. Announces European CE Mark Approval for the ADNS-300 System to Treat Refractory Epilepsy

Stroke Takes Center Stage in Kids' Hip Hop Video Competition

Posted: Published on June 7th, 2012

DALLAS, TX--(Marketwire -06/07/12)- The American Stroke Association kicks off a national hip hop stroke video competition for 10- to 15-year-olds to broaden public awareness about stroke. The free competition at http://www.strokeassociation.org/hiphopcontest engages and educates youth on stroke while igniting their creative use of visual arts. Stroke is the No. 4 cause of death and a leading cause of severe, long-term disability in America. Yet, 93 percent of Americans do not think of stroke as a major health concern, according to the American Stroke Association, a division of the American Heart Association. Integrating hip hop music with stroke education helps kids learn, retain and share stroke information with their parents and grandparents, according to research presented at the American Heart Association/American Stroke Association's International Stroke Conference in February. Kids can submit a video at http://www.strokeassociation.org/hiphopcontest as an individual or group before Sept. 21, 2012. Each video must include the American Stroke Association's official hip hop stroke song and a parent or grandparent, and demonstrate artistic ability and originality. The song, "Enlighten the World on Stroke," was written for the American Stroke Association by Atlanta-based Osiris South Records, LLC. All videos will be posted on the American Stroke Association's competition website where … Continue reading

Comments Off on Stroke Takes Center Stage in Kids' Hip Hop Video Competition

Suit: Ex-players say NFL hid brain injury links

Posted: Published on June 7th, 2012

Updated: June 7, 2012, 11:42 AM ET PHILADELPHIA -- A concussion-related lawsuit bringing together scores of cases has been filed in federal court, accusing the NFL of hiding information that linked football-related head trauma to permanent brain injuries. Lawyers for former players say more than 80 pending lawsuits are consolidated in the "master complaint" filed Thursday in Philadelphia. What is a concussion? What are the various professional sports leagues doing to prevent and treat them? ESPN.com Topics has the breakdown on all concussion-related issues. Topics Plaintiffs hope to hold the NFL responsible for the care of players suffering from dementia, Alzheimer's disease and other neurological conditions. Other former players remain asymptomatic, but worry about the future and want medical monitoring. The suit accuses the NFL of "mythologizing" and glorifying violence through the media, including its NFL Films division. "The NFL, like the sport of boxing, was aware of the health risks associated with repetitive blows producing sub-concussive and concussive results and the fact that some members of the NFL player population were at significant risk of developing long-term brain damage and cognitive decline as a result," the complaint charges. "Despite its knowledge and controlling role in governing player conduct on … Continue reading

Posted in Brain Injury Treatment | Comments Off on Suit: Ex-players say NFL hid brain injury links

Page 6,801«..1020..6,8006,8016,8026,803..6,8106,820..»